Intraoperative Telemedicine Program: ACTFAST-3 Study

By Staff Writer

September 28, 2023

Introduction to the ACTFAST-3 Study

The Anesthesiology Control Tower (ACT), a real-time telemedicine decision support system, was tested in the ACTFAST-3 Randomised Clinical Trial. The study aimed to evaluate the feasibility of the ACT and its impact on two quality of care measures: postoperative hypothermia and hyperglycemia.

The ACTFAST-3 study, a single-centre pilot superiority RCT, took place in the USA from April 2017 to June 2019. The study involved all patients aged 18 years and above who had undergone surgery. However, the study did not include patients if the ACT staff did not staff more than 50% of their case duration or if they did not suffer from diabetes (for glycemic outcomes).

Results and Implications

The pilot study, involving 26,254 patients, found that the telemedicine decision support intervention did not significantly alter the two quality of care outcomes. While there was a slight increase in intraoperative glucose measurement in the intervention group, there was no difference in the frequency of treatment for hyperglycemia. This lack of difference could explain the unchanged postoperative hyperglycemia rates.



The study also highlighted potential reasons for these results. For instance, the high adherence to each measure at baseline made significant improvements challenging. Also, the trial noted the impact of the Hawthorne effect, where changes in behaviour occur due to the awareness of being observed.

The study concluded that further optimization of clinical decision support and workflows might help the intraoperative telemedicine program achieve improvement in targeted clinical measures.

Conclusion:

The ACTFAST-3 study offers crucial insights into the application of telemedicine in anesthesiology, yet it underscores the complexity of enhancing care quality through such interventions. Despite the implementation of the Anesthesiology Control Tower, improvements in postoperative hypothermia and hyperglycemia were not evident. This outcome suggests that high baseline adherence to quality measures and behavioural modifications due to the Hawthorne effect may dilute the impact of telemedicine interventions. Consequently, to realise the potential benefits of real-time decision support systems, we must refine clinical support tools and streamline operative workflows. The findings prompt a re-evaluation of strategies within the telemedicine framework to ensure that technological advancements translate into tangible improvements in patient care. 

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.